67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
Titel:
67P Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
Auteur:
Brahmer, J.R. Ciuleanu, T-E. Schenker, M. Audigier-Valette, C. Zurawski, B. Linardou, H. Kim, S-W. Otterson, G.A. Salman, P. De La Mora Jimenez, E. Lesniewski-Kmak, K. Ahmed, S. Albert, I. Barlesi, F. Feeney, K. Frickhofen, N. Li, A. Sun, P. Hellmann, M.